Thermo Fisher Scientific Acquires Affymetrix

Thermo Fisher Scientific Acquires Brammer Bio for $1.7 Billion

March 25, 2019

Biotechnology

Thermo Fisher Scientific agreed to acquire Brammer Bio, a viral vector CDMO focused on gene and cell therapies, for approximately $1.7 billion in cash. The deal expands Thermo Fisher’s pharma services and viral vector manufacturing capabilities to support high-growth gene and cell therapy markets and brings a team of nearly 600 employees into its pharma services business.

Thermo Fisher Scientific Acquires Olink Holding AB

July 10, 2024

Biotechnology

Thermo Fisher Scientific completed the acquisition of Olink Holding AB (publ) via a public cash tender offer at USD 26.00 per share/ADS, buying the proteomics company from shareholders including Summa Equity. The acquisition strengthens Thermo Fisher’s proteomics and protein-analysis capabilities, adding Olink’s high‑multiplex protein detection technology to its life‑science tools portfolio.

Bruker Corporation to Acquire PhenomeX Inc for $108 Million

August 17, 2023

Medical Devices

Bruker Corporation has signed a definitive agreement to acquire PhenomeX Inc in an all-cash transaction valued at approximately $108 million equity value ($1.00 per share). The deal is expected to close in the fourth quarter of 2023, subject to customary closing conditions, after which PhenomeX will merge into a wholly owned Bruker subsidiary.

Thermo Fisher Scientific Acquires MarqMetrix

June 21, 2023

Medical Devices

Thermo Fisher Scientific has completed its acquisition of MarqMetrix, a Seattle-based developer of Raman-based in-line spectroscopy and Process Analytical Technology (PAT). The deal adds Raman-based in-line PAT capabilities to Thermo Fisher’s Analytical Instruments segment; terms were not disclosed.

Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

December 8, 2021

Healthcare Services

Thermo Fisher Scientific completed its acquisition of PPD, Inc., a leading global provider of clinical research services, for $17.4 billion. The deal extends Thermo Fisher’s clinical research capabilities across the drug development spectrum and is expected to generate total synergies of approximately $125 million by year three following close.

Thermo Fisher Scientific Acquires The Binding Site Group

October 31, 2022

Medical Devices

Thermo Fisher Scientific has entered into a definitive agreement to acquire The Binding Site Group from a shareholder group led by Nordic Capital for £2.25 billion (about $2.6 billion). The Binding Site, a Birmingham-based specialist in protein and blood-cancer diagnostics with more than 1,100 employees and ~10% annual revenue growth, will join Thermo Fisher's Specialty Diagnostics segment to expand its capabilities in cancer diagnostics and monitoring.